Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase I Study of LY3502970 in Healthy Participants
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to evaluate how much of the study drug (LY3502970) and the radioactive substance 14C incorporated LY3502970 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 9 weeks for each participant.
Official title: A Single-Group, Open-Label, Single-Period, Phase 1 Study to Determine the Absolute Bioavailability of LY3502970 in Healthy Participants
Key Details
Gender
All
Age Range
21 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2023-10-19
Completion Date
2024-01-05
Last Updated
2026-05-27
Healthy Volunteers
Yes
Conditions
Interventions
LY3502970
Administered orally
[14C]-LY3502970
Administered IV
Locations (1)
Covance Clinical Research Inc
Madison, Wisconsin, United States